Clavister - A Period of Transition
2021-08-31 10:20:00
Redeye has a mixed view of Clavister's 2Q21 – net sales were softer than forecast while subscription sales and order intake surprised positively. We maintain an optimistic operational outlook and expect a robust second half of 2021. We decrease our Base Case slightly but continue to see value (40%+) at current levels.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/